Filing Details
- Accession Number:
- 0000899243-19-015275
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-31 16:05:20
- Reporting Period:
- 2019-05-29
- Accepted Time:
- 2019-05-31 16:05:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1596946 | Quotient Ltd | QTNT | In Vitro & In Vivo Diagnostic Substances (2835) | 264719797 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1604628 | Jeremy Stackawitz | C/O Quotient Limited 28 Esplanade St Helier Y9 JE2 3QA | President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2019-05-29 | 21,495 | $9.93 | 131,939 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Ordinary Shares | Employee Stock Option (right to buy) | $11.92 | 2026-05-31 | 20,000 | 20,000 | Direct | |
Ordinary Shares | Employee Stock Option (right to buy) | $15.17 | 2025-05-19 | 22,500 | 22,500 | Direct | |
Ordinary Shares | Employee Stock Option (right to buy) | $8.00 | 2024-04-29 | 60,000 | 60,000 | Direct | |
Ordinary Shares | Employee Stock Option (right to buy) | $7.58 | 2027-05-23 | 40,000 | 40,000 | Direct | |
Ordinary Shares | Multi-year Performance Based Restricted Stock Unit | $0.00 | 2019-12-31 | 50,000 | 50,000 | Direct | |
Ordinary Shares | Restricted Stock Units | $0.00 | 20,641 | 20,641 | Direct | ||
Ordinary Shares | Restricted Stock Units | $0.00 | 35,000 | 35,000 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2026-05-31 | 20,000 | 20,000 | Direct |
2025-05-19 | 22,500 | 22,500 | Direct |
2024-04-29 | 60,000 | 60,000 | Direct |
2027-05-23 | 40,000 | 40,000 | Direct |
2019-12-31 | 50,000 | 50,000 | Direct |
20,641 | 20,641 | Direct | |
35,000 | 35,000 | Direct |
Footnotes
- 13,334 options have vested and remain exercisable and 6,666 options will vest on June 1, 2019.
- All 22,500 options have vested and remain exercisable.
- All 60,000 options have vested and remain exercisable.
- 26,666 options have vested and remain exercisable. 13,334 options will vest on May 24, 2020.
- Each Multi-year Performance Based Restricted Stock Unit ("MRSU") represents a contingent right to receive one share of Quotient's ordinary shares. The MRSUs vest upon Quotient's ordinary shares achieving a volume weighted average market price of $22.00 per share for 20 consecutive trading days during the period April 1, 2019 to December 31, 2019.
- Restricted Stock Units convert into ordinary shares on a one-for-one basis.
- On May 24, 2018, the Reporting Person was granted 30,961 Restricted Stock Units, of which 10,320 have vested and have been exercised. The remaining 20,641 Restricted Stock Units will vest in two equal installments on May 24, 2020 and May 24, 2021.
- On May 24, 2019, the Reporting Person was granted 35,000 Restricted Stock Units, vesting in three equal annual installments beginning May 24, 2020.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $9.98, inclusive. The Reporting Person undertakes to provide to Quotient Limited, any security holder of Quotient Limited, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (10) to this Form 4.